Gano Kyle

CEO Kyle Gano sells 36,400 shares at $132.70 avg, reducing stake by 20.6%; prior sells at NBIX timed perfectly before declines

Gano Kyle, CEO of Neurocrine Biosciences, executed 2 separate sales totaling 36,400 shares for $4,830,458.10 on 2026-01-16, reducing his post-transaction holding to 140,407 shares from 176,807 shares. His SAME-TICKER HISTORY at NBIX shows 2 prior measurable sales (2025-01-15), both achieving -18.7% at 30 days and -32.0% at 90 days—a 100% well-timed rate at the 90-day mark. The current price of $134.54 is now -13.6% from the 52-week high ($155.63), placing the stock in recent pullback territory. With the company delivering strong fundamentals ($794.9M quarterly revenue, +24.8% annual growth, $209.5M net income), the CEO's consistent pattern of selling ahead of stock declines at this specific ticker warrants investor attention regarding his forward outlook for near-term price action.

CEO Gano Kyle sells 65,000 shares (32.4% reduction) for $9.2M at $141.50; holds 135.4K shares post-sale

CEO Gano Kyle executed 2 separate sales on 2025-01-15 totaling 65,000 shares for $9,197,549.84, reducing his holdings from 200,392 to 135,392 shares (a -32.4% net reduction). The sales occurred at $141.50 per share, approximately 1.2% below the current price of $143.26 but within the recent 52-week range; the stock has gained 5.8% over 30 days and 21.4% over 90 days. At the same-ticker level, Kyle's prior 2 sales at NBIX (both on 2024-01-02) showed positive 90-day returns of 7.5% and 7.6%, meaning the stock rose after those sales—neither was well-timed in the sell-timing sense. This sale occurs in a company posting strong financial performance: $622.1M revenue in the latest quarter, $129.8M net income, 26.8% annual revenue growth, and a $14.5B market cap at a 37.60 P/E. The magnitude of the equity reduction warrants monitoring but the timing relative to recent price momentum and his historical pattern at this ticker does not indicate outsized conviction about near-term downside.